Benzinga | Jul 20, 2020 09:18AM EDT

Roth Capital Initiates Coverage On Global Blood Therapeutics with Buy Rating, Announces Price Target of $129

Roth Capital analyst Elemer Piros initiates coverage on Global Blood Therapeutics (NASDAQ:GBT) with a Buy rating and announces Price Target of $129.